Fabrication of novel nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl }-phenyl-methanone] Ru(III) complex for pharmaceutical applications
A nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex, its synthesis, and its use as an anticancer, antioxidant, and antimicrobial agent.
1. A nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex having the formula I:
2. The nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 , wherein the complex has a spherical shape.
3. The nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 , wherein the complex has a size of about 20 nm.
4. A pharmaceutically acceptable composition comprising the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 and a pharmaceutically acceptable carrier.
5. A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 .
6. The method of treating cancer of claim 5 , wherein the cancer is colon cancer.
7. A method of treating a microbial infection in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 .
8. The method of treating the microbial infection of claim 7 , wherein the microbial infection is caused by a gram negative bacteria Pseudomonas aeruginosa.
9. The method of treating the microbial infection of claim 7 , wherein the microbial infection is caused by a fungus Aspergillus Flavus.
10. A method of inhibiting free radicals in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 .
11. A method of promoting an antioxidant activity in a subject, the method comprising administering to a subject in need thereof the pharmaceutical composition of claim 4 .
12. A method of making the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 1 , the method comprising:
adding RuCl 3 in ethanol to a 4{3,4-Bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone azomethine ligand in ethanol to obtain a reaction mixture;
sonicating the reaction mixture a first time;
adding a secondary ligand phenanthroline to the reaction mixture under sonication a second time; and
obtaining the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex.
13. The method of making nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein the RuCl 3 in ethanol is added stepwise.
14. The method of making nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein sonicating the reaction mixture a first time lasts for about 30 minutes.
15. The method of making nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein sonicating the reaction mixture a second time lasts for about 30 minutes.
16. The method of making nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein the RuCl 3 and the 4{3,4-Bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone azomethine ligand are added in an about 2:1 molar ratio.
17. The method of making the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein the RuCl 3 , the 4{3,4-Bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone azomethine ligand, and the secondary ligand phenanthroline are added in an about 2:1:1 molar ratio.
18. The method of making nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex of claim 12 , wherein the nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex is obtained as a dark brown crystalline powder.